Threat Modeling for NeuroTech & BCIs
Threat models for BCIs, DBS, and closed-loop neuromodulation - STRIDE/TARA traced to ISO 14971, with implant, programmer, and patient-app trust boundaries.
Last reviewed March 2026 · Reviewed against the FDA Feb 3, 2026 final premarket cybersecurity guidance.
NeuroTech threat modeling has to handle a system with three distinct trust domains - implant, clinician programmer, patient-side companion - and a closed-loop control path inside the implant itself. Reviewers expect to see STRIDE applied per data-flow across all of those boundaries, not a single block diagram with a few arrows. Our threat models for this segment use STRIDE-per-element on a system data-flow diagram that includes the in-implant sense-stim loop as a first-class boundary, then trace each identified threat to a risk control in your ISO 14971 file and an SPDF mitigation.
We model the wireless link to the implant explicitly: pairing, session, command authorization, and parameter-write authorization as separate controls. We model the patient app as compromised by default and verify that no implant control depends on app-side enforcement. We model the clinician programmer as both a trusted clinician tool and a potentially stolen device, and demand differentiated controls for each. For closed-loop systems we add a control-integrity threat-modeling pass: which elements of the sense-to-stim pipeline can be tampered with, and what is the patient-harm scenario if they are? Output is an AAMI SW96-aligned threat model document that maps cleanly to your hazard analysis, plus a security architecture view that satisfies FDA's 'global system view' expectation for implantables.
Layers we exercise in this engagement
The neurotech / bci system, from the outermost cloud and clinician surfaces down to the device itself. Highlighted layers are exercised by this medical device threat modeling.
- 01Cloud APIs Tested
- 02Patient remote Tested
- 03Clinician programmer Tested
- 04Wireless link Tested
- 05Implant firmware Tested
- 06Closed-loop sensing Tested
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Medical Device Threat Modeling engagement, end to end
Four phases, fixed fee, scoped to neurotech / bci architecture from kickoff onward.
-
01
Architecture intake
Data-flow diagrams, trust boundaries, and asset inventory captured directly from your design team.
-
02
STRIDE workshop
Joint working sessions to enumerate threats per element, mapped to Section 524B(b) and AAMI SW96.
-
03
Risk + mitigation pass
Each threat gets a residual-risk rating, mitigation, and a link to the verification activity that proves it.
-
04
Reviewer-ready package
Threat model document and SPDF section ready to drop straight into eSTAR cybersecurity attachments.
What we see in NeuroTech / BCI medical device threat modeling
The patterns we hit in this segment, this service, again and again.
-
Stolen-programmer scenario absent from threat file
Programmer modeled only as 'clinician in clinic'. Stolen-device, lost-device, and after-hours scenarios not analyzed - reviewer flagged this in pre-sub.
-
Closed-loop sense path treated as trusted
Sense-to-stim path inside implant assumed trusted. Bench fault-injection scenarios not in scope of threat model.
-
Patient-app compromise not assumed
Implant authorization model trusts app's representation of user identity. Rooted-device threat scenario missing.
-
Postmarket update path not threat-modeled
Update channel assumed safe because 'signed firmware'. Threat model doesn't cover compromise of the signing infra or rollback attacks.
"Blue Goat's niche expertise in FDA-facing cybersecurity made all the difference. Their reports were built with the FDA's expectations in mind - it gave us confidence that we were submitting exactly what reviewers want to see."
Standard Medical Device Threat Modeling deliverables
The same deliverables the parent Medical Device Threat Modeling service ships with - tuned to your neurotech / bci architecture.
- ANSI/AAMI SW96 + ISO 14971 alignment
- End-to-end medical device system coverage
- Threat-to-mitigation traceability
- Justified methodology and assumptions
What lands in your eSTAR submission
Reviewer-format documents ready to drop straight into the cybersecurity attachments of your submission - no reformatting on your side.
- ANSI/AAMI SW96 + ISO 14971 alignment
- End-to-end medical device system coverage
- Threat-to-mitigation traceability
- Justified methodology and assumptions
Standards that apply
The NeuroTech / BCI baseline, plus the call-outs that matter for medical device threat modeling in this segment.
Segment-specific call-outs
ANSI/AAMI SW96 + ISO 14971 traceability
Every threat must trace to a risk control. We deliver a threat-to-control matrix in the format reviewers expect.
AAMI TIR97 (postmarket)
For implantables, the threat model must include the postmarket update and CVD pathways, not just the as-shipped device.
What's not in scope
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
- Penetration testing execution (scoped separately)
- Clinical risk analysis under ISO 14971 (we feed it, we do not own it)
- Hospital network architecture review
Medical Device Threat Modeling for NeuroTech / BCI - FAQs
The questions buyers in this segment actually ask before scoping a medical device threat modeling engagement.
Go deeper on NeuroTech / BCI and premarket
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
250+ 0 6–10 wk FDA submissions supported Cybersecurity rejections Class II eSTAR cyber pack SINCE 2014 TRACK RECORD TYPICAL TIMELINE
Learn the specific cybersecurity requirements for a successful De Novo submission. Ensure FDA compliance with threat modeling, SBOM, and pen testing.
The threat intelligence sources medical device manufacturers should monitor to satisfy FDA Section 524B postmarket obligations: H-ISAC, CISA KEV, ICS advisories, NVD, MITRE ATT&CK for ICS, and vendor PSIRTs.
FMEA covers random and systematic failure modes; threat modeling covers adversarial action. Both are required for a 524B submission, and they do not substitute for each other. Here is how to scope them, link them, and avoid the gap.
What the FDA expects from infusion pump cybersecurity submissions in 2026: threat model focus areas, Section 524B evidence, and the deficiencies that delay clearance.
Other engagements for NeuroTech / BCI
Teams in this segment commonly bundle these alongside medical device threat modeling.
Keep going
Scope a Medical Device Threat Modeling engagement for your neurotech / bci program.
A 30-minute call with a senior engineer who has done this in neurotech / bci before - not a sales rep.